# A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

> **NCT03292172** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 36 (actual)

## Conditions studied

- Advanced Ovarian Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** RO6870810

## Key facts

- **NCT ID:** NCT03292172
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-08
- **Primary completion:** 2019-02-26
- **Final completion:** 2019-02-26
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Portfolio prioritization
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292172, "A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03292172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*